Ligand Pharmaceuticals Incorporated
General ticker "LGND" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.5B (TTM average)
Ligand Pharmaceuticals Incorporated follows the US Stock Market performance with the rate: 63.4%.
Estimated limits based on current volatility of 2.5%: low 199.11$, high 209.44$
Factors to consider:
- Total employees count: 68 (+17.2%) as of 2024
- Top business risk factors: Operational and conduct risks, Supply chain disruptions, Partnership program failure, Economic downturns and volatility, Regulatory and compliance
- Current price 36.9% above estimated high
- Earnings for 12 months up through Q4 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [97.48$, 143.95$]
- 2025-12-31 to 2026-12-31 estimated range: [102.71$, 150.71$]
Financial Metrics affecting the LGND estimates:
- Negative: with PPE of 197.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: Shareholder equity ratio, % of 88.18 > 64.29
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0.15 <= 0.73
- Positive: 0.01 < Operating cash flow per share per price, % of 4.71
Short-term LGND quotes
Long-term LGND plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $196.25MM | $133.44MM | $152.08MM |
| Operating Expenses | $193.21MM | $121.49MM | $174.68MM |
| Operating Income | $3.04MM | $11.94MM | $-22.61MM |
| Non-Operating Income | $32.97MM | $51.72MM | $25.12MM |
| Interest Expense | $1.80MM | $0.66MM | $3.04MM |
| R&D Expense | $36.08MM | $24.54MM | $21.43MM |
| Income(Loss) | $36.01MM | $63.66MM | $2.52MM |
| Taxes | $41.23MM | $9.84MM | $6.55MM |
| Other Income(Loss) | $-28.14MM | $-1.67MM | $0.00MM |
| Profit(Loss)* | $-61.50MM | $50.49MM | $-4.03MM |
| Stockholders Equity | $597.49MM | $700.91MM | $830.44MM |
| Inventory | $13.29MM | $23.97MM | $14.11MM |
| Assets | $762.67MM | $787.22MM | $941.77MM |
| Operating Cash Flow | $137.85MM | $49.58MM | $97.05MM |
| Capital expenditure | $17.92MM | $53.85MM | $19.64MM |
| Investing Cash Flow | $163.62MM | $-11.68MM | $-143.66MM |
| Financing Cash Flow | $-275.99MM | $-59.95MM | $97.14MM |
| Earnings Per Share** | $-3.65 | $2.92 | $-0.22 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.